» Articles » PMID: 31446616

BRCA-1 Depletion Impairs Pro-inflammatory Polarization and Activation of RAW 264.7 Macrophages in a NF-κB-dependent Mechanism

Overview
Publisher Springer
Specialty Biochemistry
Date 2019 Aug 26
PMID 31446616
Citations 2
Authors
Affiliations
Soon will be listed here.
Abstract

BRCA-1 is a nuclear protein involved in DNA repair, transcriptional regulation, and cell cycle control. Its involvement in other cellular processes has been described. Here, we aimed to investigate the role of BRCA-1 in macrophages M(LPS), M(IL-4), and tumor cell-induced differentiation. We used siRNAs to knockdown BRCA-1 in RAW 264.7 macrophages exposed to LPS, IL-4, and C6 glioma cells conditioned medium (CMC6), and evaluated macrophage differentiation markers and functional phagocytic activity as well as DNA damage and cell survival in the presence and absence of BRCA-1. LPS and CMC6, but not by IL-4, increased DNA damage in macrophages, and this effect was more pronounced in BRCA-1-depleted cells, including M(IL-4). BRCA-1 depletion impaired expression of pro-inflammatory cytokines, TNF-α and IL-6, and reduced the phagocytic activity of macrophages in response to LPS. In CMC6-induced differentiation, BRCA-1 knockdown inhibited TNF-α and IL-6 expression which was accompanied by upregulation of the anti-inflammatory markers IL-10 and TGF-β and reduced phagocytosis. In contrast, M(IL-4) phenotype was not affected by BRCA-1 status. Molecular docking predicted that the conserved BRCA-1 domain BRCT can interact with the p65 subunit of NF-κB. Immunofluorescence assays showed that BRCA-1 and p65 co-localize in the nucleus of LPS-treated macrophages and reporter gene assay showed that depletion of BRCA-1 decreased LPS and CMC6-induced NF-κB transactivation. IL-4 had no effect upon NF-κB. Taken together, our findings suggest a role of BRCA-1 in macrophage differentiation and phagocytosis induced by LPS and tumor cells secretoma, but not IL-4, in a mechanism associated with inhibition of NF-κB.

Citing Articles

Recent advancements in nanomaterial-based biosensors for diagnosis of breast cancer: a comprehensive review.

Yazdani Y, Jalali F, Tahmasbi H, Akbari M, Talebi N, Shahrtash S Cancer Cell Int. 2025; 25(1):50.

PMID: 39966938 PMC: 11834589. DOI: 10.1186/s12935-025-03663-8.


Drug resistance in ovarian cancer: from mechanism to clinical trial.

Wang L, Wang X, Zhu X, Zhong L, Jiang Q, Wang Y Mol Cancer. 2024; 23(1):66.

PMID: 38539161 PMC: 10976737. DOI: 10.1186/s12943-024-01967-3.


BRCT Domains: Structure, Functions, and Implications in Disease-New Therapeutic Targets for Innovative Drug Discovery against Infections.

Pena-Guerrero J, Fernandez-Rubio C, Garcia-Sosa A, Nguewa P Pharmaceutics. 2023; 15(7).

PMID: 37514027 PMC: 10386641. DOI: 10.3390/pharmaceutics15071839.

References
1.
Brune B, Dehne N, Grossmann N, Jung M, Namgaladze D, Schmid T . Redox control of inflammation in macrophages. Antioxid Redox Signal. 2013; 19(6):595-637. PMC: 3718318. DOI: 10.1089/ars.2012.4785. View

2.
Gordon S, Martinez F . Alternative activation of macrophages: mechanism and functions. Immunity. 2010; 32(5):593-604. DOI: 10.1016/j.immuni.2010.05.007. View

3.
Gordon S . Alternative activation of macrophages. Nat Rev Immunol. 2003; 3(1):23-35. DOI: 10.1038/nri978. View

4.
Bonder C, Dickensheets H, Finlay-Jones J, Donnelly R, Hart P . Involvement of the IL-2 receptor gamma-chain (gammac) in the control by IL-4 of human monocyte and macrophage proinflammatory mediator production. J Immunol. 1998; 160(8):4048-56. View

5.
Cheung D, Hart P, Vitti G, Whitty G, Hamilton J . Contrasting effects of interferon-gamma and interleukin-4 on the interleukin-6 activity of stimulated human monocytes. Immunology. 1990; 71(1):70-5. PMC: 1384223. View